Edward E. Lehman has been asked to write a China article by PharmSource

(prHWY.com) September 10, 2011 - Beijing, China -- Edward E. Lehman has been asked to write a China article on an upcoming issue of the newsletter by PharmSource, a respected provider of business intelligence on contract drug development and manufacture. The article is about SFDA regulatory requirements on cross-border pharmaceutical contract manufacturing activities. And it will discuss the changes made to current standards in China and any implications for bio/pharmaceutical companies and contract manufacturing organizations and will explore product rights issues for contract manufacturing relationships in the country.

Some of the questions will be involved in the newsletter:
1. What was the impetus behind the SFDA decision to implement new regulatory requirements on domestic contract manufacturing activities for foreign pharmaceutical manufacturers?
2. What will be the impact of eliminating third-party agents from the contract manufacturing agreement process?

So let's wait and expect what Mr. Lehman's viewpoint and explanation will be to answer those questions in the forthcoming edition of newsletter. And the title would be Emerging Markets Outsourcing Report (EMOR).

###